Florida Cancer Specialists & Research Institute (FCS) announced the appointment of Joel Grossman, MD, and Maen Hussein, MD, to its executive board.
Joel Grossman, MD, and Maen Hussein, MD, have been appointed to the executive board at Florida Cancer Specialists & Research Institute (FCS), the organization have announced.
“Dr Grossman and Dr Hussein are outstanding physicians who always strive to do more to ensure that patients have the best possible care experience,” Lucio N. Gordan, MD, FCS president and managing physician, said. “Their willingness to serve on the executive board is further evidence of their commitment to delivering world-class cancer care in community settings.”
Grossman, a board-certified medical oncologist, has been a part of FCS since 2003. He practices oncology in Naples where he also serves as the Division Chief of Oncology and Hematology for the Naples Comprehensive Health Healthcare System. This recent appointment will mark Grossman’s fourth term on the FCS executive board. He presently serves as a member of the Electronic Medical Record (EMR) committee and previously served as the inaugural chair of the compensation committee.
Hussein—who also serves on the finance committee at FCS—has been with FCS since 2011 and has worked as the primary investigator in many clinical trials focusing on lung cancer. He has been a very active participant in cancer research and finds lots of value in clinical trial efforts. At present, he practices at FCS Brownwood and Villages Cancer Center, as well as serves as president of the Florida Society of Clinical Oncology board of directions. Furthermore, he is an active member of the board of directors and the previous chair of the FCS Foundation.
“Our executive board members have a significant impact on the direction we take and the decisions we make in this highly dynamic and rapidly changing environment," Nathan H. Walcker, MBA, FCS chief executive officer, said. "We value the expertise and insights these physicians will contribute to achieving our mission, vision, and strategic priorities.”
The Silver Lining: Progress and Promise in Combating STIs
December 3rd 2024With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the current novel approaches in STI care and learn about crucial next steps to combat this public health issue.
Read More
CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity
December 2nd 2024The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.
Read More
Expert Insights on How Utilization Management Drives Physician Burnout
November 26th 2024On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.
Listen
sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS
November 29th 2024The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.
Read More
Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines
November 29th 2024With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
Read More